08:00 | Registration |
| Emerging Biomarkers in Cancer |
| |
08:30 | | Keynote Presentation Detection and Clinical Implications of Circulating Tumor Cells in Cancer Patients Klaus Pantel, Chairman, Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany
Detection and characterization of CTC opens a new avenue for understanding metastatic spread of tumor cells with important implications for future therapies. Implementation of CTC analyses in clinical trials testing new anti-cancer agents as companion diagnostics will speed up the cumbersome and expensive drug validation process in oncology. |
|
09:30 | Detection and Characterization of Viable Circulating Tumor Cells Catherine Alix-Panabieres, Associate Professor, University Medical Center of Montpellier, France
The enumeration and characterization of circulating tumor cells (CTCs) in the peripheral blood and disseminated tumor cells (DTCs) in bone marrow may provide important prognostic information and might help to monitor efficacy of therapy. |
10:15 | Coffee Break and Networking in the Exhibition Hall |
10:35 | The Worldwide Market Landscape for Exosomes: Research and Translational Opportunities Enal Razvi, Managing Director, Select Biosciences Inc, United States of America
SELECTBIO has been tracking the qualitative and quantitative trends and opportunities in the exosomes and microvesicles marketplace. In this presentation, I provide an up-to-date snapshot of this evolving marketplace excerpted from SELECTBIO's various market reports on this topic. Presented are technologies for exosome analysis, segmentation of the exosome research market, market penetrance of various approaches for exosome study, disciplines/disease areas where exosome research is currently being carried out, and sizes of some of the market segments in this space—both from a basic research and a translational standpoint. |
11:20 | Molecular Characterization of Circulating Tumor Cells Evi Lianidou, Professor, University of Athens, Greece
Circulating Tumor Cell (CTC) analysis is a promising new diagnostic field for cancer patients towards the estimation of risk for metastatic relapse or metastatic progression. Molecular characterization of CTC can provide important information on the molecular and biologic nature of these cells and is very important for the identification of therapeutic targets and resistance mechanisms in CTC, as well as for the stratification of patients and real-time monitoring of systemic therapies. |
| Sequencing in Rapid Disease Diagnosis |
| |
12:05 | | Keynote Presentation The Promise of Next Generation Sequencing for Infectious Disease Diagnostics Till Bachmann, Reader, University of Edinburgh, United Kingdom
The adoption of molecular diagnostics of infectious diseases and antibiotic resistance is well on the rise, serving an ever increasing demand for rapid results which can be obtained at the point of care. The advent of next generation sequencing technologies is now set to revolutionise these applications in infectious disease diagnostics, outbreak tracking and personalised medicine. |
|
13:05 | Technology Spotlight: Nanoparticle Tracking Analysis – A Novel Technique for Exosomes Research Thomas Benen, Sales Manager, Microtrac
The technique of Nanoparticle Tracking Analysis from NanoSight Ltd is a recently developed method which is being rapidly adopted for the analysis and counting of exosomes and microvesicles. Based on a unique microscopical laser illumination configuration, this technique allows biological nanoparticles in a sample to be simultaneously but individually visualised, sized (through video analysis of their Brownian motion) and counted in real time and in complex backgrounds. Furthermore, it is capable of detecting and analysing fluorescently labelled exosomes and microvesicles allowing for phenotyping of subpopulations of such structures in clinical samples. The technique will be described and selected examples will be shown from the 250+ papers describing the use of NTA in the routine analysis of biological samples of clinical significance in a wide range of applications concentrating on the use of exosomes and microvesicles in diagnosis and therapeutics. |
13:20 | Lunch and Networking in Exhibition Hall |
13:35 | Poster Viewing Session |
| Applications of Exosomes in Diagnostics |
| |
14:15 | Towards an Exosomes-based Molecular Test for Remission Monitoring of Cancer Michiel Pegtel, Associate Professor, Cancer Center Amsterdam, VU University Medical Center, Netherlands
In this presentation Next-Gen sequencing is used to explore the complex small RNAome in exosomes and how this technique maybe useful for future biomarker studies in large patient groups. |
15:00 | Proteomic Analysis of Human Urinary Exosomes in Diabetic Nephropathy, Potential Markers of Disease Gloria Alvarez-Llamas, Senior Investigator, IIS-Fundacion Jimenez Diaz, Spain
Proteomic analysis of human urinary exosomes revealed specific alterations in diabetic nephropathy and a panel of three candidate markers to be monitored for disease diagnosis and follow-up. |
15:45 | | Keynote Presentation Role of Exosomes in Neurodegeneration Lawrence Rajendran, Velux Stiftung Professor for Systems and Cell Biology of Neurodegeneration, University of Zurich, Switzerland
Professor Rajendran will discuss the role of secreted microvesicles and exosomes in neurodegenerative diseases such as Alzheimer's and Parkinsons's disease. |
|
16:30 | Coffee Break and Networking in the Exhibition Hall |
| Cancer Personalised Medicine |
| |
16:50 | Fast-Tracking Molecular Diagnostics in Oncology via Antibody-Based Proteomics and Digital Pathology William Gallaghr, Chief Scientific Officer/Professor, OncoMark Limited/University College Dublin, Ireland
This presentation will cover the utility of antibody-based profiling using tissue microarrays and associated digital pathology approaches to expedite the transition from biomarker discovery to validation in oncology. Case studies covering a range of cancer and biomarker types will be outlined. |
17:35 | Enrichment of Genomic Fractions for Mutations Prior to Sequencing using COLD-PCR Mike Makrigiorgos, Professor, Dana-Farber Cancer Institute/Harvard Medical School, United States of America
Rare mutations in clinical samples can have major prognostic and predictive implications, yet they are difficult to detect using sequencing. We present novel enhancements in COLD-PCR technology that enable enrichment of mutations in large genomic fractions prior to high throughput sequencing, thus enabling their detection. |
18:20 | Next Generation Sequencing and its Impact on Clinical Oncology Robert Loewe, Chief Executive Officer, Genewake, Germany
NextGen sequencing increasingly enters the area of everyday clinical routine. After an overview of the NGS development until today, current and future applications of this technology in the field of oncology, e.g. screening of specific biomarkers, will be demonstrated. |
19:05 | End of Day One |